Evidence brief
Semax
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Semax is a synthetic seven-amino-acid peptide studied mainly in Russia. Small human studies measured stroke-recovery scales, pain scores, blood markers, or brain scans. These studies do not prove that Semax improves focus or treats disease. Semax is not an FDA-approved U.S. drug. A 2026 advisory vote did not add it to the current 503A list.
Semax is a seven-amino-acid peptide. FDA has not approved it. Human studies do not prove a benefit.
- How strong is the evidence?
- Emerging
Some studies in people exist. Important questions remain about benefit, safety, who it helps, or how long the effects last. This is not an approval or recommendation. - What evidence exists?
- Investigational human outcomes
Studies measured health results in people, but the molecule is still being studied and is not approved for that use. Important questions remain. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed August 30, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Heptapeptide Semax. Heptapeptide means a peptide with seven amino acids.
Words used here
- peptide
- a short chain of amino acids
- investigational
- still being studied and not approved for that use
- outcome
- what the study measured
- molecule
- one specific chemical substance
- mechanism
- how a substance may cause a body change
- biomarker
- a body or lab measurement, not automatically a health benefit
- route
- how the product enters the body
- amino acid
- a small building block that makes peptides and proteins
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Small and limited human studies do not establish the focus, memory, or treatment claims made online.
FDA found no human pharmacokinetic studies, which measure how the body handles a drug. Human exposure and effects are not well characterized.
Most safety reports were small or incomplete. FDA found no under-the-skin (subcutaneous) safety data and raised impurity, peptide-clumping (aggregation), immune-response, and bleeding concerns.
The free base and acetate are separate forms, and the reviewed record does not show that online products match either form or the studied material.
02 · Identity
What it is
Semax is a peptide made of seven amino acids: Met-Glu-His-Phe-Pro-Gly-Pro. FDA says it is a changed form of ACTH(4-10), which is a small part of a body hormone. Russia has registered Semax as 0.1% and 1% nose drops. FDA reviewed Semax free base and Semax acetate as separate chemical forms. N-acetyl Semax amidate is another modified substance.
Scientific group: Seven-amino-acid peptide. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
None identified in the United States.
- Human research after stroke
- Small human studies of migraine and trigeminal neuralgia
04 · Research results
What the research shows
FDA reviewed Semax for reduced blood flow to the brain, migraine, and severe facial pain. They found too little proof for all three uses. A 1997 stroke study compared 30 Semax-treated people with 80 people who received standard care. Its abstract did not say how large the change was. A 2018 stroke study followed 110 people, but its abstract did not show random group assignment or blinding. The 12-person migraine and 25-person facial-pain groups had no control group or blinding.
Studies do not show that Semax improves focus, memory, attention, or daily function. A 24-person study measured links on brain scans. It did not test thinking or daily function. FDA found no human study of how the body handles Semax. It found no safety data for use under the skin. Most reports gave few safety details. FDA warned about impurities, peptide clumps, immune reactions, and possible bleeding. No record shows an online product matches the form or study material.
Exact product
Semax free base and Semax acetate are distinct chemical forms. A product name does not show which form it contains or whether it matches the material studied. N-acetyl Semax amidate is a different modified substance, not a Semax alias.
05 · Claim check
Claims I checked
6 claims checked for this brief.
“Semax is a seven-amino-acid peptide.”
FDA identifies Semax as a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. This identifies the free-base peptide and does not make other chemical forms or products interchangeable.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Semax free base as identified in FDA's substance and briefing records; the acetate form is a separate chemical form. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Semax improves focus or memory, or treats ADHD.”
FDA found no supporting literature for ADHD. A 24-person study measured resting brain-scan connections, not focus, memory, attention, or daily function.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- Focus, memory, and ADHD claims made for Semax; not a finding about the laboratory or animal literature. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Semax treats stroke, migraine, or severe facial pain.”
FDA staff found insufficient evidence of effectiveness for cerebral ischemia, migraine, or trigeminal neuralgia. The two stroke studies listed here have important design and comparison limits.
- Evidence used
- No reliable human outcome evidence. No reliable study in people shows the health outcome in this statement.
- Limits of this answer
- The uses reviewed by FDA in 2026; this does not assess every possible research question. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
Show 3 more claim checks
“Semax is FDA-approved in the United States.”
FDA says Semax free base and Semax acetate are not components of an FDA-approved drug. A drug registered in Russia does not create U.S. approval.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- United States approval status as reviewed August 30, 2026. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“The advisory vote added Semax to the 503A list or approved it.”
RAPS reported an 8-5 advisory-committee vote in favor of adding Semax to the 503A list. FDA says advisory recommendations are non-binding, and the briefing says FDA had not made its final determination. No final FDA rule or listing was identified in this review.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The July 2026 advisory vote and U.S. 503A status as reviewed August 30, 2026; a recommendation is not a final FDA decision or drug approval. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Semax free base, Semax acetate, and N-acetyl Semax amidate are interchangeable.”
FDA identifies Semax free base and Semax acetate as distinct active ingredients. PubChem identifies N-acetyl Semax amidate as a chemically modified substance. A shared name does not establish the same structure, quality, safety, or evidence.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Chemical-form and product-identity comparisons; this is not a use or administration recommendation. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Semax
No. An advisory vote gives advice to the FDA. It was not final FDA approval or a final listing decision for Semax. The vote did not add Semax to the current 503A list, and it does not make an online or compounded product FDA-approved.
Registered in Russia; no FDA-approved U.S. product or final 503A listing was identified as reviewed August 30, 2026. No approved product is identified in the United States.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
FDA reviewed Semax for reduced blood flow to the brain, migraine, and severe facial pain. They found too little proof for all three uses. A 1997 stroke study compared 30 Semax-treated people with 80 people who received standard care. Its abstract did not say how large the change was. A 2018 stroke study followed 110 people, but its abstract did not show random group assignment or blinding. The 12-person migraine and 25-person facial-pain groups had no control group or blinding.
Studies do not show that Semax improves focus, memory, attention, or daily function. A 24-person study measured links on brain scans. It did not test thinking or daily function. FDA found no human study of how the body handles Semax. It found no safety data for use under the skin. Most reports gave few safety details. FDA warned about impurities, peptide clumps, immune reactions, and possible bleeding. No record shows an online product matches the form or study material.
07 · Safety
Safety limits for this record
This guide does not provide dosing, route, sourcing, product-selection, or treatment advice. A Russian registration or an advisory vote does not prove U.S. approval, product quality, or personal safety.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Reviewed FDA's 2026 Semax briefing and advisory-committee record, FDA's substance record, human stroke and brain-scan studies, and the chemical record for N-acetyl Semax amidate.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.